Skip to main content

Table 6 Sensitivity analysis comparison of net benefits after excluding missing values in the validation cohorts

From: Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies

Risk thresholds

Validation Cohort 1

Validation Cohort 2

Net benefit (95% CI)

Net benefit (95% CI)

bpMRI PI-RADS v2.1-based model

 10%

0.277 (0.210, 0.347)

0.340(0.268, 0.432)

 15%

0.252 (0.191, 0.329)

0.320(0.242, 0.407)

 20%

0.249 (0.178, 0.318)

0.296(0.222, 0.387)

bpMRI PI-RADS v2.1-based model after excluding missing values

 10%

0.308 (0.227, 0.386)

0.357 (0.276, 0.459)

 15%

0.283 (0.210, 0.368)

0.338 (0.248, 0.427)

 20%

0.271 (0.196, 0.348)

0.320 (0.228, 0.407)

  1. bpMRI biparametric Magnetic Resonance Imaging, PI-RADS v2.1 Prostate Imaging Reporting and Data System version 2.1, CI confidence interval